The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Education
  • Automotive
  • Sports

New Version of HLN's Award Winning Open Source Immunization Forecaster Released
The PennZone/10055828

Trending...
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
Sample ICE Patient Evaluation and Forecast NVPO UpShot Award HLN Consulting, LLC
Innovative open source software, originally developed for public health, is freely available to EHR and PHR systems to support clinical decision support for immunizations.

PALM DESERT, Calif. - PennZone -- On February 12, 2020, HLN released a new version (v1.22.1) of the Immunization Calculation Engine (ICE). ICE is a state-of-the-art open-source software system that provides clinical decision support for immunizations for use in Immunization Information Systems (IIS), Electronic Health Record (EHR) and Personal Health Record (PHR) Systems.

This version includes important updates including:
  • Logic updates to the Pneumococcal Vaccine Group following the latest ACIP guidance.
  • Logic corrections for the DTP Vaccine Group and Influenza Vaccine Group.
  • A minor modification to how month-based calculations are performed.
  • More user-friendly wording for the evaluation reason text and recommendation reason text.
  • A new option which, when enabled, returns the supplemental text for evaluations and recommendations where applicable. For the appropriate pneumococcal recommendations, ICE utilizes this feature to return supplemental text that recommends shared clinical decision making, and cites the relevant MMWR.
  • A new option which, when enabled, allows client applications to override how ICE would normally evaluate a specified shot (i.e., client applications can indicate that an administered immunization being submitted to ICE for evaluation must be treated as INVALID or VALID per an input parameter).
  • ICE now outputs the version of the ICE service in each response.

The full software release is available for download at https://cdsframework.atlassian.net/wiki/display/ICE/Downloads.

More on The PennZone
  • Nearly One-Third of CRE Asset Managers Make Major Capital Decisions on Gut Instinct, New Survey Finds
  • RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Grace Montessori School Earns Prestigious American Montessori Society Accreditation

The Immunization Calculation Engine, or ICE, is a fully configurable vaccine forecasting/decision support web service tool. Making patient-specific vaccine decisions based on US Government American Council on Immunization Practices (ACIP) clinical recommendations is a very complex task. It requires translating ACIP recommendations - the detailed rules that examine a patient's immunization history and determine if all vaccinations are valid, and what vaccinations might be missing - into computable language for clinical decision support. ICE evaluates a patient's immunization history and generates the appropriate immunization recommendations for the patient. These recommendations are communicated to the clinician at the point of care, as well as the patient, health department or other users.

In developing ICE, HLN worked with the New York City Citywide Immunization Registry (CIR), the Alabama Department of Public Health, and the OpenCDS collaboration which is led by researchers at the University of Utah, Department of Biomedical Informatics. ICE is now in use or being configured for use by several governmental Immunization Information Systems (including in the states of Michigan, New Jersey, Rhode Island, and Vermont, as well as New York City), electronic health record (EHR) systems (including eClinicalWorks, some Centricity sites, and the Indian Health Service's RPMS), the AZOVA Digital Health Marketplace, and the CareDox personal health record. Other EHRs, personal health record (PHR) systems, and Health Information Exchanges (HIEs) can be easily adapted to incorporate ICE logic and clinical decision support into their systems as well.

More on The PennZone
  • Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach

Please feel free to e-mail ice@hln.com if you have any questions.

About HLN

For more than twenty years, HLN has been a leading public health informatics consulting company focused on developing and supporting robust technical solutions addressing pressing public health needs. HLN is dedicated to the development, improvement, promulgation, and use of Open Source solutions in health information technology. Much of our Open Source work is focused on clinical decision support (CDS) applications built using OpenCDS, an open source clinical decision support platform, including our Immunization Calculation Engine (ICE) and Reportable Condition Knowledge Management System (RCKMS) which is supporting the national strategy of electronic case reporting to public health. RCKMS is being funded by the Centers for Disease Control and Prevention (CDC) through the Council of State and Territorial Epidemiologists (CSTE) and deployed centrally to determine if a patient's symptoms and conditions require reporting to one or more public health jurisdiction.

More information on HLN Consulting and its open source products can be found at https://www.hln.com.

Contact
Noam H. Arzt, PhD
arzt@hln.com
8585382220


Source: HLN Consulting, LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
  • Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 773
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 111
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 106
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Crossroads4Hope Announces The Lipschutz Women's Fund

Similar on PennZone

  • Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
  • When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us